• Publications
  • Influence
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Summary Background Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However, thisExpand
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
BACKGROUND Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere. Expand
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
OBJECTIVE To update recommendations for antiretroviral therapy for adult human immunodeficiency virus type 1 (HIV-1) infection, based on new information and drugs that are available. PARTICIPANTS AExpand
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
BACKGROUND The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz. METHODS In this multicentre, open-label, randomisedExpand
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
OBJECTIVE New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start, what drugs to start with, when to change, and what to change to. TheseExpand
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
CONTEXT Guidelines for antiretroviral therapy are important for clinicians worldwide given the complexity of the field and the varied clinical situations in which these agents are used. TheExpand
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
PURPOSE The effect of highly active antiretroviral therapy (HAART) on the incidence of non-AIDS-defining cancers (NADCs) is unclear. METHODS We have investigated the occurrence of NADCs in aExpand
Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome
Objectives Many questionnaires on adherence to antiretroviral therapy are in use, but the validity of patients’ responses has not been tested. The Medication Adherence Self-Report Inventory (MASRI)Expand
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Objective:To characterize the safety profile of tenofovir disoproxil fumarate (DF) for the treatment of HIV infection in adults over the first 4 years of use. Methods:A tenofovir DF expanded accessExpand
Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.
HIV infection is associated with immune dysfunction, perturbation of immune-cell subsets and opportunistic infections. CD161++ CD8+ T cells are a tissue-infiltrating population that produce IL17A,Expand
...
1
2
3
4
5
...